Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan
Movement Disorders Clinical Practice · 2026
DOI: 10.1002/mdc3.70259 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Nobutaka Hattori und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Sialorrhea, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Teijin Pharma.
Abstract (Originalsprache)
Background
Sialorrhea, caused by various neurological diseases, impairs patient health and quality of life. After the results of a randomized controlled trial, incobotulinumtoxinA was approved for the treatment of chronic sialorrhea in the United States and Europe; however, no pharmacotherapy has been approved in Japan.
Objective
The aim was to evaluate the efficacy and safety of incobotulinumtoxinA treatment for chronic sialorrhea in a single‐arm phase 3 study in Japan.
Methods
Patients with chronic sialorrhea caused by neurological diseases (Parkinson's disease, atypical parkinsonism, and stroke, group A) and broader diseases (eg, muscular dystrophy and amyotrophic lateral sclerosis, group B) were enrolled. IncobotulinumtoxinA 100 U was injected into the salivary glands once every 16 weeks for 48 weeks. A primary endpoint was assessed in group A, whereas secondary endpoints and safety were assessed in both groups.
Results
From November 2021 to August 2023, 92 patients (58 and 34 in groups A and B, respectively) received incobotulinumtoxinA at 28 institutions. The primary endpoint, the least square mean (standard error) of change in unstimulated salivary flow rate from baseline to 4 weeks, was −0.08 (0.009, 95% confidence interval [CI]: −0.10, −0.06) g/min, achieving the prespecified efficacy criteria (upper limit of the 95% CI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Neurology, National Center of Neurology and Psychiatry, Tokyo, Japan.
- Department of Neurology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
- Department of Neurology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Neurology, Fukuoka University, Fukuoka, Japan.
ORCID-Profile: Nobutaka Hattori, Yohei Mukai, Noriko Nishikawa, Kazuko Hasegawa, Yasuyoshi Kimura, Yoshio Tsuboi, Ryosuke Takahashi, Ryota Nakamura, Yuishin Izumi, Hirohisa Watanabe, Morinobu Seki, Kenji Sekiguchi
Förderung
- Teijin Pharma
Zitieren
APA
Hattori, N., Mukai, Y., Nishikawa, N., Hasegawa, K., Tomiyama, M., Kimura, Y., Tsuboi, Y., Takahashi, R., Nakamura, R., Izumi, Y., Watanabe, H., Seki, M., Sekiguchi, K., Tateishi, S., Matsushita, Y., & Nakamura, Y. (2026). Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70259
Vancouver
Hattori N, Mukai Y, Nishikawa N, Hasegawa K, Tomiyama M, Kimura Y, et al. Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70259
BibTeX
@article{Hattori2026,
author = {Hattori, Nobutaka and Mukai, Yohei and Nishikawa, Noriko and Hasegawa, Kazuko and Tomiyama, Masahiko and Kimura, Yasuyoshi and Tsuboi, Yoshio and Takahashi, Ryosuke and Nakamura, Ryota and Izumi, Yuishin and Watanabe, Hirohisa and Seki, Morinobu and Sekiguchi, Kenji and Tateishi, Shohei and Matsushita, Yusaku and Nakamura, Yusaku},
title = {Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan},
journal = {Movement Disorders Clinical Practice},
year = {2026},
doi = {10.1002/mdc3.70259}
}
EUVIMED